The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Opinion 09-1
20090284: Unilever N.V.; Mascolo Brothers Limited
20090272: Olympus Growth Fund V, L.P.; Kocher-Plastik H. Bohmer GmbH & Co. KG
0902004 Informal Interpretation
Apparel Rules Agency Information Collection Activities; Submission for OMB Review; Comment Request
20090250: Yucaipa American Alliance (Parallel) Fund II, L.P.; Barnes & Noble, Inc.
20090277: Morgan Stanley; Morgan Stanley Smith Barney LLC
0902005 Informal Interpretation
Teva Pharmaceutical Industries Ltd., a corporation, and Barr Pharmaceuticals, Inc., a corporation, In the Matter of
In December 2008, the Commission settled antitrust concerns raised by the proposed $8.9 billion acquisition of Barr Pharmaceuticals by Teva Pharmaceutical Industries. The proposed acquisition would have lessened competition in the markets for 17 commonly used generic medications including drugs used in the treatment of cancer, bacterial infections, diabetes, acid reflux, and depression as well as several varieties of oral contraceptives. According to the Commission’s complaint, the acquisition would have likely led to higher prices for consumers through the removal of one of only four competitors in each of these markets. The Commission’s consent agreement requires both Teva and Barr to sell assets in 29 U.S. markets to either Watson Pharmaceuticals or Qualitest Pharmaceuticals.